ECSP22083269A - ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) - Google Patents

ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)

Info

Publication number
ECSP22083269A
ECSP22083269A ECSENADI202283269A ECDI202283269A ECSP22083269A EC SP22083269 A ECSP22083269 A EC SP22083269A EC SENADI202283269 A ECSENADI202283269 A EC SENADI202283269A EC DI202283269 A ECDI202283269 A EC DI202283269A EC SP22083269 A ECSP22083269 A EC SP22083269A
Authority
EC
Ecuador
Prior art keywords
cov
sars
monoclonal antibodies
directed against
human monoclonal
Prior art date
Application number
ECSENADI202283269A
Other languages
English (en)
Inventor
Robert Carnahan
Seth Zost
Pavlo Gilchuk
James E Crowe
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of ECSP22083269A publication Critical patent/ECSP22083269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Abstract

La presente divulgación se refiere a anticuerpos que se unen a y neutralizan el coronavirus denominado SARS-CoV-2 y a métodos de uso de los mismos.
ECSENADI202283269A 2020-03-26 2022-10-26 ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) ECSP22083269A (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202063000299P 2020-03-26 2020-03-26
US202063002896P 2020-03-31 2020-03-31
US202063003716P 2020-04-01 2020-04-01
US202063023545P 2020-05-12 2020-05-12
US202063024248P 2020-05-13 2020-05-13
US202063024204P 2020-05-13 2020-05-13
US202063027173P 2020-05-19 2020-05-19
US202063037984P 2020-06-11 2020-06-11
US202063040224P 2020-06-17 2020-06-17
US202063040246P 2020-06-17 2020-06-17
US202163142196P 2021-01-27 2021-01-27
US202163161890P 2021-03-16 2021-03-16

Publications (1)

Publication Number Publication Date
ECSP22083269A true ECSP22083269A (es) 2022-11-30

Family

ID=75540042

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202283269A ECSP22083269A (es) 2020-03-26 2022-10-26 ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)

Country Status (28)

Country Link
US (2) US11345741B2 (es)
EP (2) EP4356924A2 (es)
JP (1) JP2023518849A (es)
KR (1) KR20220158053A (es)
CN (1) CN115768790A (es)
AU (1) AU2021242306A1 (es)
BR (1) BR112022018949A2 (es)
CA (1) CA3175110A1 (es)
CL (1) CL2022002594A1 (es)
CO (1) CO2022014820A2 (es)
CR (1) CR20220545A (es)
DK (1) DK4045533T3 (es)
DO (1) DOP2022000199A (es)
EC (1) ECSP22083269A (es)
FI (1) FI4045533T3 (es)
HR (1) HRP20240182T1 (es)
HU (1) HUE065039T2 (es)
IL (1) IL296537A (es)
LT (1) LT4045533T (es)
MX (1) MX2022011892A (es)
PE (1) PE20230415A1 (es)
PL (1) PL4045533T3 (es)
PT (1) PT4045533T (es)
RS (1) RS65199B1 (es)
SI (1) SI4045533T1 (es)
TW (1) TW202200610A (es)
UY (1) UY39135A (es)
WO (1) WO2021195418A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020234A2 (en) * 2020-07-20 2022-01-27 Bio-Rad Laboratories, Inc. Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor
WO2022034044A1 (en) * 2020-08-10 2022-02-17 Astrazeneca Uk Limited Sars-cov-2 antibodies for treatment and prevention of covid-19
US11440952B2 (en) 2020-10-16 2022-09-13 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
TW202342095A (zh) * 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
WO2023108936A1 (zh) * 2021-12-14 2023-06-22 杭州安旭生物科技股份有限公司 一种可结合SARS-CoV-2病毒的中和抗体及其应用
WO2023209177A1 (en) * 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
CN114870061A (zh) * 2022-05-31 2022-08-09 康码（上海）生物科技有限公司 一种基于病毒阻断剂的空气喷雾剂及其用途
WO2024019110A1 (ja) * 2022-07-20 2024-01-25 国立感染症研究所長が代表する日本国 ＳＡＲＳ－ＣｏＶ－２に対する抗体
CN115925934A (zh) * 2022-07-26 2023-04-07 北京昌平实验室 一种稳定性提高的人源化单克隆抗体及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2002079255A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
SE520605C2 (sv) 2001-06-29 2003-07-29 Flir Systems Ab Optiskt system innefattande en detektor och en bländare med decentreringsfunktion
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1874824A4 (en) 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
US20110159001A1 (en) * 2008-01-17 2011-06-30 Institute For Research In Biomedicine CROSS-NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES TO SARS-CoV AND METHODS OF USE THEREOF
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
BR112022015374A2 (pt) * 2020-02-03 2022-10-11 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
ES2954629T3 (es) * 2020-02-26 2023-11-23 Vir Biotechnology Inc Anticuerpos contra SARS-CoV-2
US11053304B1 (en) * 2020-03-23 2021-07-06 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 6nb6

Also Published As

Publication number Publication date
DOP2022000199A (es) 2022-11-30
AU2021242306A1 (en) 2022-11-17
CN115768790A (zh) 2023-03-07
EP4045533B1 (en) 2023-11-15
US20210300999A1 (en) 2021-09-30
MX2022011892A (es) 2022-10-18
KR20220158053A (ko) 2022-11-29
FI4045533T3 (fi) 2024-02-02
RS65199B1 (sr) 2024-03-29
US11345741B2 (en) 2022-05-31
UY39135A (es) 2021-10-29
CA3175110A1 (en) 2021-09-30
PT4045533T (pt) 2024-02-14
US20220281958A1 (en) 2022-09-08
CR20220545A (es) 2023-01-09
HRP20240182T1 (hr) 2024-04-26
LT4045533T (lt) 2024-02-26
IL296537A (en) 2022-11-01
PL4045533T3 (pl) 2024-04-15
EP4045533A1 (en) 2022-08-24
BR112022018949A2 (pt) 2022-11-08
PE20230415A1 (es) 2023-03-07
JP2023518849A (ja) 2023-05-08
HUE065039T2 (hu) 2024-04-28
WO2021195418A1 (en) 2021-09-30
EP4356924A2 (en) 2024-04-24
CO2022014820A2 (es) 2022-10-21
CL2022002594A1 (es) 2023-06-02
DK4045533T3 (da) 2024-02-12
SI4045533T1 (sl) 2024-03-29
TW202200610A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
ECSP22083269A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CO2019010943A2 (es) Anticuerpos de unión a vista a ph ácido
CL2020002410A1 (es) Anticuerpos de unión a vista a ph ácido
CL2020002539A1 (es) Anticuerpos multiespecíficos anti-hla-g y utilización de los mismos
ECSP21052194A (es) Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
CL2021000258A1 (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
DOP2023000172A (es) Moduladores de cot y métodos de uso de los mismos
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CO2021000046A2 (es) Anticuerpos de unión a vista a ph ácido
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
CL2023000701A1 (es) Anticuerpos que se unen a il1rap y usos de los mismos
AR121370A1 (es) Anticuerpos anti-cd19 humano
CO2023008643A2 (es) Anticuerpos anti-hla-g y uso de estos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
CL2022002833A1 (es) Anticuerpos anti-flt3 y composiciones
CL2022000627A1 (es) Anticuerpos de unión a vista a ph ácido
CO2021016982A2 (es) Métodos de uso de una construcción biespecífica de unión al antígeno dirigida a her2 para el tratamiento de cánceres de las vías biliares
BR112021021060A2 (pt) Anticorpos anti-cd38 e formulações
BR112021024176A2 (pt) Anticorpos anti-angpt2
CL2023000916A1 (es) Anticuerpos con capacidad de unirse a ror2 y anticuerpos biespecíficos que se unen a ror2 y cd3.
AR115001A1 (es) ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO